Pierre Fabre Medicament

This study is testing an experimental cell therapy called tabelecleucel for transplant patients who develop a rare cancer caused by Epstein-Barr virus. The treatment uses specially prepared immune cells to target and fight the virus-related cancer in patients who haven't responde…

This study is testing a new drug called STX-721/PFL-721 for people with advanced non-small cell lung cancer that has specific genetic mutations (EGFR or HER2 exon 20 insertions). The trial aims to find the safest and most effective dose while checking if the drug can shrink tumor…

This study is testing a new oral medication called STX-241 for people with advanced non-small cell lung cancer (NSCLC) that has continued to grow despite treatment with standard targeted drugs (EGFR TKIs). The main goals are to find a safe and effective dose and to see if the dru…

This study is testing whether an experimental cell therapy called tabelecleucel can help control diseases caused by the Epstein-Barr virus in people with weakened immune systems. The trial includes 190 participants who have developed serious conditions like lymphomas or sarcomas …